VCM
VERV

Versant Capital Management’s Verve Therapeutics VERV Stock Holding History

Versant Capital Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-980
Closed -$11K – 2727
2025
Q2 		$11K Buy
980
+167
+21% +$952 ﹤0.01% 1850
2025
Q1 		$3.71K Buy
813
+609
+299% +$4.08K ﹤0.01% 2135
2024
Q4 		$1.15K Sell
204
-119
-37% -$671 ﹤0.01% 2164
2024
Q3 		$1.56K Buy
+323
New +$1.88K ﹤0.01% 1635

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Versant Capital Management's VERV Position: Q3 2025 in Review

Versant Capital Management sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 980 shares — an estimated $11K sold.

Versant Capital Management first reported a position in VERV in Q3 2024 and held it in 4 quarters. The position peaked at $11K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Versant Capital Management reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Versant Capital Management sold 980 Verve Therapeutics shares in Q3 2025, an estimated $11K.
  • Versant Capital Management first reported a position in Verve Therapeutics in Q3 2024 and held it in 4 quarters.
  • Versant Capital Management's Verve Therapeutics position peaked at $11K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Versant Capital Management's 13F filing for Q3 2025, filed 27 Oct 2025.